Targeting HER2 + breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles

Hynes, 2005, ERBB receptors and cancer: the complexity of targeted inhibitors, Nat. Rev. Cancer, 5, 341, 10.1038/nrc1609 Mendelsohn, 2000, The EGF receptor family as targets for cancer therapy, Oncogene, 19, 6550, 10.1038/sj.onc.1204082 Roepstorff, 2008, Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer, Histochem. Cell Biol., 129, 563, 10.1007/s00418-008-0401-3 Hudis, 2007, Trastuzumab — mechanism of action and use in clinical practice, N. Engl. J. Med., 357, 39, 10.1056/NEJMra043186 Albanell, 2003, Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4, 253 Baselga, 2001, Mechanism of action of anti-HER2 monoclonal antibodies, Ann. Oncol., 12, 35, 10.1093/annonc/12.suppl_1.S35 Austin, 2004, Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin, Mol. Biol. Cell, 15, 5268, 10.1091/mbc.e04-07-0591 Vu, 2012, Trastuzumab: updated mechanisms of action and resistance in breast cancer, Front. Oncol., 2, 62, 10.3389/fonc.2012.00062 Karamouzis, 2007, Trastuzumab — mechanism of action and use, N. Engl. J. Med., 357, 39, 10.1056/NEJMra043186 Sliwkowski, 1999, Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin), Semin. Oncol., 26, 60 Sorkin, 2009, Endocytosis and intracellular trafficking of ErbBs, Exp. Cell Res., 315, 683, 10.1016/j.yexcr.2008.07.029 Kitano, 2007, Assessment of a new anti-HER2 monoclonal antibody, SV2-61 gamma: a best concordance with HER2 FISH, Appl. Immunohistochem. Mol. Morphol., 15, 389, 10.1097/PAI.0b013e31802f411c Nordstrom, 2011, Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fc gamma receptor binding properties, Breast Cancer Res., 13, 10.1186/bcr3069 Tabatabaei-Panah, 2008, Production and characterizing anti-HER2 monoclonal antibodies, Yakhteh, 10, 109 Wong, 2012, Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer, Int. J. Breast Cancer, 2012, 10.1155/2012/415170 Bostrom, 2011, High affinity antigen recognition of the dual specific variants of Herceptin is entropy-driven in spite of structural plasticity, PLoS One, 6, e17887, 10.1371/journal.pone.0017887 Sidhu, 2007, Phage display for engineering and analyzing protein interaction interfaces, Curr. Opin. Struct. Biol., 17, 481, 10.1016/j.sbi.2007.08.007 Fellouse, 2007, High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries, J. Mol. Biol., 373, 924, 10.1016/j.jmb.2007.08.005 Erickson, 2006, Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing, Cancer Res., 66, 4426, 10.1158/0008-5472.CAN-05-4489 Girish, 2012, Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer, Cancer Chemother. Pharmacol., 69, 1229, 10.1007/s00280-011-1817-3 Lewis Phillips, 2008, Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate, Cancer Res., 68, 9280, 10.1158/0008-5472.CAN-08-1776 Shi, 2009, Doxorubicin-conjugated immuno-nanoparticles for intracellular anticancer drug delivery, Adv. Funct. Mater., 19, 1689, 10.1002/adfm.200801271 Torchilin, 2004, Targeted polymeric micelles for delivery of poorly soluble drugs, Cell. Mol. Life Sci., 61, 2549, 10.1007/s00018-004-4153-5 Wagner, 2007, Programmed drug delivery: nanosystems for tumor targeting, Expert. Opin. Biol. Ther., 7, 587, 10.1517/14712598.7.5.587 Cheng, 2011, Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives, Chem. Soc. Rev., 40, 2673, 10.1039/c0cs00097c Namiki, 2011, Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring, Acc. Chem. Res., 44, 1080, 10.1021/ar200011r Nobs, 2004, Current methods for attaching targeting ligands to liposomes and nanoparticles, J. Pharm. Sci., 93, 1980, 10.1002/jps.20098 Sunderland, 2006, Targeted nanoparticles for detecting and treating cancer, Drug Dev. Res., 67, 70, 10.1002/ddr.20069 Sievers, 2013, Antibody–drug conjugates in cancer therapy, Annu. Rev. Med., 64, 15, 10.1146/annurev-med-050311-201823 Fay, 2011, Antibody-targeted nanoparticles for cancer therapy, Immunotherapy, 3, 381, 10.2217/imt.11.5 Schrama, 2006, Antibody targeted drugs as cancer therapeutics, Nat. Rev. Drug Discov., 5, 147, 10.1038/nrd1957 Junttila, 2011, Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer, Breast Cancer Res. Treat., 128, 347, 10.1007/s10549-010-1090-x Sutherland, 2006, Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates, J. Biol. Chem., 281, 10540, 10.1074/jbc.M510026200 Senter, 2012, The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma, Nature Biotech, 30, 631, 10.1038/nbt.2289 Bhattacharyya, 2012, Switching the targeting pathways of a therapeutic antibody by nanodesign, Angew. Chem. Int. Ed., 51, 1563, 10.1002/anie.201105432 Bhattacharyya, 2010, Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis, Proc. Natl. Acad. Sci. U. S. A., 107, 14541, 10.1073/pnas.1006507107 Liu, 2009, Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells, Mol. Pharm., 6, 959, 10.1021/mp8002682 Shi, 2007, Immuno-polymeric nanoparticles by Diels–Alder chemistry, Angew. Chem. Int. Ed. Engl., 46, 6126, 10.1002/anie.200701032 Lu, 2010, Self-assembled polymeric nanoparticles of organocatalytic copolymerizated d, l-lactide and 2-methyl 2-carboxytrimethylene carbonate, Macromolecules, 43, 4943, 10.1021/ma1004265 Howard, 2006 Lu, 2011, Stability of self-assembled polymeric micelles in serum, Macromolecules, 44, 6002, 10.1021/ma200675w Chan, 2013, Double click: dual functionalized polymeric micelles with antibodies and peptides, Bioconjug. Chem., 24, 105, 10.1021/bc300511a Howard, 2007 Dunn, 2011, A practical guide to evaluating colocalization in biological microscopy, Am. J. Physiol. Cell Physiol., 300, C723, 10.1152/ajpcell.00462.2010 Kao, 2009, Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery, PLoS One, 4, 10.1371/journal.pone.0006146 Casey, 2010, Sensors and regulators of intracellular pH, Nat. Rev. Mol. Cell Biol., 11, 50, 10.1038/nrm2820 Neckers, 2002, Hsp90 inhibitors as novel cancer chemotherapeutic agents, Trends Mol. Med., 8, S55, 10.1016/S1471-4914(02)02316-X Widdison, 2006, Semisynthetic maytansine analogues for the targeted treatment of cancer, J. Med. Chem., 49, 4392, 10.1021/jm060319f Valabrega, 2007, Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer, Ann. Oncol., 18, 977, 10.1093/annonc/mdl475 Nagy, 2005, Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line, Cancer Res., 65, 473 Lin, 2012, Pharmacokinetic considerations for antibody drug conjugates, Pharm. Res., 29, 2354, 10.1007/s11095-012-0800-y Axup, 2012, Synthesis of site-specific antibody–drug conjugates using unnatural amino acids, Proc. Natl. Acad. Sci. U. S. A., 109, 16101, 10.1073/pnas.1211023109 Wu, 2005, Arming antibodies: prospects and challenges for immunoconjugates, Nat. Biotechnol., 23, 1137, 10.1038/nbt1141